



HAL
open science

TRANSIENT ELASTOGRAPHY AND BIOMARKERS FOR LIVER FIBROSIS ASSESSMENT AND FOLLOW-UP OF INACTIVE HEPATITIS B CARRIERS

Laurent Castera, Pierre-Henri Bernard, Brigitte Lebail, Juliette Foucher,
Pascale Trimoulet, Wassil Merrouche, Patrice Couzigou, Victor de Ledinghen

► **To cite this version:**

Laurent Castera, Pierre-Henri Bernard, Brigitte Lebail, Juliette Foucher, Pascale Trimoulet, et al..
TRANSIENT ELASTOGRAPHY AND BIOMARKERS FOR LIVER FIBROSIS ASSESSMENT
AND FOLLOW-UP OF INACTIVE HEPATITIS B CARRIERS. *Alimentary Pharmacology and Ther-*
apeutics, 2010, 33 (4), pp.455. 10.1111/j.1365-2036.2010.04547.x . hal-00602613

HAL Id: hal-00602613

<https://hal.science/hal-00602613>

Submitted on 23 Jun 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**TRANSIENT ELASTOGRAPHY AND BIOMARKERS FOR LIVER
FIBROSIS ASSESSMENT AND FOLLOW-UP OF INACTIVE
HEPATITIS B CARRIERS**

Journal:	<i>Alimentary Pharmacology & Therapeutics</i>
Manuscript ID:	APT-0748-2010.R1
Wiley - Manuscript type:	Original Scientific Paper
Date Submitted by the Author:	24-Oct-2010
Complete List of Authors:	Castera, Laurent; C.H.U Bordeaux, Hopital Haut Leveque, Hepatogastroenterology Bernard, Pierre-Henri; C.H.U. Bordeaux, Hopital St-Andre, Hepatogastroenterology LeBail, Brigitte; C.H.U Bordeaux, Hopital Pellegrin, Pathology Foucher, Juliette; C.H.U. Bordeaux, Hopital haut Leveque, Hepatogastroenterology Trimoulet, Pascale; Chu bordeaux, Virology Merrouche, wassil; CHU Bordeaux, hepatogastroenterology Couzigou, Patrice; CHU Bordeaux, hepatogastroenterology de ledinghen, Victor; Hopital Haut Leveque, C.H.U. Bordeaux, Hepatogastroenterology
Keywords:	Hepatitis B < Hepatology, Liver fibrosis < Hepatology, Viral hepatitis < Hepatology, Liver biopsy < Hepatology

1
2
3 **TRANSIENT ELASTOGRAPHY AND BIOMARKERS FOR LIVER FIBROSIS**
4
5 **ASSESSMENT AND FOLLOW-UP OF INACTIVE HEPATITIS B CARRIERS**
6
7
8

9
10 Laurent Castéra (1, 2), Pierre-Henri Bernard (2), Brigitte Le Bail (3), Juliette Foucher (1, 2),
11
12 Pascale Trimoulet (4), Wassil Merrouche (1), Patrice Couzigou (1) and Victor de Lédighen (1).
13
14

15
16
17 (1) Service d'Hépatogastroentérologie, Hôpital Haut-Lévêque, Centre Hospitalier Universitaire
18
19 (C.H.U.) Bordeaux, Pessac; France

20
21
22 (2) Service d'Hépatogastroentérologie, Hôpital St-André, C.H.U. Bordeaux, Bordeaux; France

23
24
25 (3) Service d'Anatomo-Pathologie, Hôpital Pellegrin, C.H.U. Bordeaux, Bordeaux; France

26
27
28 (4) Laboratoire de Virologie, Hôpital Pellegrin, C.H.U. Bordeaux, Bordeaux, France
29
30
31
32

33
34 Correspondence to: Laurent CASTERA, MD, PhD
35
36 Service d'Hépatogastroentérologie,
37
38 Hôpital Haut Lévêque, C.H.U. Bordeaux
39
40 Avenue Magellan, 33604 Pessac, France.
41
42
43 Tel: 00 33 5 57 65 64 39
44
45 Fax: 00 33 5 57 65 64 45
46
47 e-mail: laurent.castera@chu-bordeaux.fr
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT**Aim**

To evaluate longitudinally transient elastography (TE) and biomarkers for liver fibrosis assessment and follow-up of hepatitis B virus (HBV) inactive carriers.

Methods

Three hundred and twenty-nine consecutive HBeAg-negative HBV patients (201 inactive carriers) who underwent TE, Fibrotest® and APRI the same day were studied.

Results

TE (median 4.8 vs. 6.8 kPa, $p<0.0001$), Fibrotest® (0.16 vs. 0.35, $p<0.0001$) and APRI values (0.28 vs. 0.43, $p<0.0001$) were significantly lower in inactive carriers than in the remaining patients whereas they did not differ between inactive carriers according to HBV DNA levels. In 82 inactive carriers with repeated examinations, although differences were observed among individual patients, TE values did not differ significantly over time (median intra-patient changes at end of follow-up relative to baseline: -0.2 kPa, $p=0.12$). Conversely, significant fluctuations were observed for Fibrotest® (+0.03, $p=0.012$) and APRI (-0.01, $p<0.05$). Eleven inactive carriers (5.5%) had initial elevated TE values (>7.2 kPa) confirmed during follow-up in two with significant fibrosis (F2 and F3) on liver biopsy.

Conclusions

Non invasive tools, particularly transient elastography, could be useful, in addition to HBV DNA and transaminase levels, for follow-up of HBV inactive carriers as well as better selection of patients who require a liver biopsy.

INTRODUCTION

Chronic hepatitis B virus (HBV) infection with negative Hepatitis B e antigen (HBeAg) is becoming the predominant type of chronic HBV infection worldwide (1), as well as in France (2). The clinical spectrum of HBeAg-negative chronic HBV infection may range from the inactive chronic HBsAg carrier state, characterized by persistently normal alanine aminotransferase (ALT) values, low or undetectable viremia and no liver injury to active chronic hepatitis B with elevated ALT activity, high HBV DNA levels, and active liver histological lesions. It is important and sometimes difficult to distinguish true inactive carriers (IC) from patients with active HBeAg-negative chronic active hepatitis B (CHB) in whom phases of spontaneous remission may occur (3). IC have a good prognosis with a very low risk of complications and need just to be followed up regularly (1). Differential diagnosis with CHB is based largely on careful monitoring of ALT activity, serum HBV DNA levels, and liver histology. Although liver biopsy remains the reference method for assessment of liver disease severity in chronic HBV infection, it is currently not recommended in IC (4, 5). In addition, liver biopsy is a painful and invasive procedure (6, 7) with rare but potentially life-threatening complications (8, 9), and prone to sampling errors (10, 11). These limitations have stimulated the search for new non invasive approaches (12-14). A variety of methods including the measurement of liver stiffness, using transient elastography (TE) and biomarkers, ranging from routinely available non patented scores such as APRI to more complex patented algorithms such as the Fibrotest® (FT), have been proposed for the noninvasive assessment of hepatic fibrosis, mainly in chronic hepatitis C (15-20). Validation of these methods in hepatitis B is ongoing (21-24) but longitudinal data are still pending. The aim of this longitudinal study was to evaluate the value of TE and biomarkers (FT and APRI) for liver fibrosis assessment and follow-up of HBV inactive carriers.

PATIENTS & METHODS

Patients

Between June 2003 and June 2009, 412 patients were referred to our center for HBeAg-negative HBV-infection. The diagnosis of chronic HBV infection was based on the presence in serum of HBsAg and anti-HBe antibodies for greater than six months. Patients with other viral infection (HIV (n=11), HCV (n=7), HDV (n=5)), other causes of liver disease (n=17), and unsuccessful liver stiffness measurements (n=43) were excluded from the study. Finally, 329 patients were analyzed. Two hundred and one patients were considered as IC on the basis of persistently normal ALT and AST and HBV DNA $<10^5$ copies/ml ($<20\ 000$ IU/ml) on at least 2 determinations during the past 6 months which corresponded to the IC definition when the study was initiated (25). The remaining patients (n=128) were considered as HBeAg-negative chronic hepatitis (CHB). IC patients were also analyzed according to the new HBV DNA threshold of 2000 IU/ml proposed by EASL guidelines in 2009 (4).

All patients were enrolled after giving their written informed consent to the study which was approved by the Local Ethics Committee.

Liver histology and staging of liver fibrosis

Liver biopsy was performed according to clinical needs by senior operators using the Menghini technique with a 1.6-mm-diameter needle (Hepafix[®], Braun, Melsungen, Germany). Biopsy specimens were fixed in formalin and embedded in paraffin. All biopsy specimens were analyzed by the same trained pathologist blinded to the results of non invasive tests.

Liver fibrosis and necro-inflammatory activity were evaluated semi-quantitatively according to the METAVIR scoring system (26, 27). Fibrosis was staged on a 0-4 scale, as follows: F0, no

1
2
3 fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis and few septa; F3, numerous septa
4
5 without cirrhosis; F4, cirrhosis. Activity was graded as follows: A0, none; A1, mild; A2,
6
7 moderate; A3, severe.
8
9

10 Two clinically relevant end points were chosen: significant fibrosis ($F \geq 2$) and cirrhosis (F4).
11
12 The presence of significant fibrosis in HBV patients is considered a hallmark of a progressive
13
14 liver disease and an indication for antiviral treatment and the presence of cirrhosis triggers
15
16 screening for complications such as oesophageal varices and hepatocellular carcinoma (4)
17
18
19
20
21

22 **Liver stiffness measurement**

23
24 Liver stiffness measurements were performed using TE (FibroScan®, Echosens, Paris,
25
26 France). Details of the technical background and examination procedure have been previously
27
28 described (28). Ten successful measurements were performed on each patient. The success rate
29
30 was calculated as the number of validated measurements divided by the total number of
31
32 measurements. The results were expressed in kilopascals (kPa). The median value of successful
33
34 measurements was considered representative of the liver stiffness in a given patient, according to
35
36 the manufacturer's recommendations (interquartile range (IQR) less than 30% of the median
37
38 value and success rate > 60%). Unsuccessful results were defined as either failure (no valid
39
40 measurement) or unreliable results (valid measurements <10 or success rate <60% or interquartile
41
42 range (IQR) >30% of median value) (29). The cut-offs used for diagnosing significant fibrosis
43
44 and cirrhosis were those proposed by Marcellin *et al.* (21) in French patients (7.2 kPa and 11.0
45
46 kPa, respectively).
47
48
49
50
51

52 Liver stiffness measurements were repeated over time (every 6 to 12 months) since 2005 in IC
53
54 patients, particularly in those with initial elevated liver stiffness values (>7.2 kPa). In case of
55
56 elevated liver stiffness values on at least two examinations, a liver biopsy was proposed.
57
58
59
60

Serum biomarkers

The parameters allowing the calculation of FT and APRI were determined in the same laboratory on blood sampled at the time of TE. The FT score was purchased from Biopredictive website (www.biopredictive.com). The APRI was calculated according to the original formula as follows: AST levels divided by its upper normal limit / platelet count ($10^9/L$) x 100 (18). The cut-offs used for diagnosing significant fibrosis and cirrhosis were those from original publications: FT values > 0.48 and > 0.74, respectively (19); APRI values < 0.5 or ≥ 1.5 and <1 or ≥ 2 , respectively (18).

Statistical analysis

Patient characteristics are given as mean \pm SD or as median and range as appropriate. Comparisons between groups were performed using nonparametric tests, including the Mann and Whitney test (2 groups) or the Kruskal-Wallis test (3 groups). Comparisons between groups for qualitative data were performed using Chi-square test or Fisher's exact test when necessary. Intra-group comparisons were made using Wilcoxon's test for paired data. Tests were two-tailed and p-values <0.05 were considered significant.

Receiver operating characteristics (ROC) curves were constructed. Sensitivity (Se), specificity (Sp), positive and negative predictive values (PPV and NPV), positive likelihood ratio (+LR) and negative likelihood ratio (-LR) were calculated using cut-offs previously described for significant fibrosis and cirrhosis for TE, FT and APRI. Also for TE, cut-offs were established in our population according to ROC curve in order to maximize Se and Sp. Areas under ROC curve (AUROC) were calculated using the trapezoidal rule. Comparisons of AUROCs were done using the method described by Hanley and McNeil for correlated data (30). Initially, we compared all AUROCs, and in case of rejection of the null hypothesis (all AUROCs are equal), differences

1
2
3 were searched for by two-by-two comparisons, using Bonferroni adjustment for multiple
4
5 pairwise comparisons. Analyses were performed using SPSS software (Statistical Systems,
6
7 Kayville, UT) and Stata V8.0 (StataCorp 2003. Stata Statistical Software: release 8.0. College
8
9 Station, TX).
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

RESULTS

Patients

The baseline characteristics of the 329 patients are shown in table 1. There were 205 men (62%), and their mean age was 39 ± 14 years. Among these patients, 60 underwent a liver biopsy. The mean liver biopsy length was 22.6 ± 8.0 mm. As expected, IC were significantly younger (36 ± 12 vs. 44 ± 16 yrs, respectively, $p < 0.0001$), were less often male (54% vs. 76%, respectively, $p < 0.0001$), and had lower HBV DNA ($1.5 \pm 2.7 \cdot 10^3$ vs. $7.4 \pm 27.9 \cdot 10^6$ IU/L, respectively, $p = 0.0002$) than CHB patients.

Cross-sectional study

Comparative diagnostic performance of TE and biomarkers for fibrosis staging

In the 60 patients who underwent a liver biopsy, activity grade and fibrosis score were as follows: A0-A1 (n=25); A2 (n=22); A3 (n=13) and F0-F1 (n=16); F2 (n=16); F3 (n=13); F4 (n=15). Diagnostic performances of TE and biomarkers are shown in Table 2.

TE, FT and APRI had similar performance for $F \geq 2$ (AUROC (95% CI): 0.76 (0.63-0.90), 0.71 (0.58-0.85), and 0.66 (0.50-0.82), respectively, $p = \text{NS}$). Conversely, for F4 TE had better performance than FT (0.89 (0.80-0.98) vs. 0.74 (0.58-0.90), respectively, $p = 0.03$) but not different from APRI (0.89 (0.80-0.98) vs. 0.79 (0.67-0.91), respectively, $p = \text{NS}$). The TE cut-offs optimized in our population were: 7.1 kPa for significant fibrosis ($F \geq 2$) and 9.6 kPa for cirrhosis (F4), respectively.

Comparison of TE and biomarkers between inactive carriers and HBeAg-negative disease

IC had significantly lower liver stiffness values (median: 4.8 (4.1 - 5.8) vs. 6.8 (4.9 - 9.5) kPa, respectively; $p < 0.0001$), FT values (median: 0.16 (0.10 - 0.25) vs. 0.35 (0.19 - 0.60), respectively;

1
2
3 p<0.0001) and APRI values (median: 0.28 (0.22 - 0.35) vs. 0.43 (0.29 - 0.72), respectively;
4
5 p<0.0001) than CHB patients (Figure 1).
6
7

8 Interestingly, eleven IC (5.5%) had elevated liver stiffness values (≥ 7.2 kPa) suggestive of
9
10 significant fibrosis (Table 3). All were offered follow-up and their characteristics are detailed
11
12 below in the longitudinal study chapter.
13
14

15 16 17 *Comparison of TE and biomarkers according to HBV DNA levels in inactive carriers*

18
19 The distribution of serum HBV DNA levels among IC was as follows: undetectable (<12
20
21 IU/mL), 33 (16%); 12 < < 2 000 IU/mL, 139 (65%); and 2 000 < < 20 000 IU/mL, 39 (19%).
22
23 Patients with HBV DNA levels < 2 000 IU/mL (81%) correspond to the recently proposed EASL
24
25 definition for IC (4) whereas patients with HBV DNA levels < 20 000 IU/mL correspond to the
26
27 classical definition (25). IC did not differ according to serum HBV DNA levels for baseline
28
29 characteristics (age, gender, BMI, ALT and AST) as well as for liver stiffness values, FT and
30
31 APRI values (Figure 2).
32
33
34
35
36
37
38

39 **Longitudinal study**

40
41 Among the 201 IC, 82 underwent repeated TE and biomarkers determinations: 2
42
43 determinations (n=82) (median interval of 11.5 months; range: 3.3-26.8); 3 determinations (n=48)
44
45 (median 23.1 months; range: 10.1-34.7), and 4 determinations (n=27) (median 34.4 months;
46
47 range: 21.6-49.1). When pooling the different time points for the 82 patients, taking into account
48
49 the last available time point (end of follow-up), the median interval was: 21.7 months (range: 3.3-
50
51 49.1). These 82 patients did not differ from the other IC for baseline characteristics (age, gender,
52
53 BMI, ALT, AST, platelet count), FT and APRI except for liver stiffness values (median 5.0 vs.
54
55 4.6 kPa, respectively, p=0.005). Indeed, as mentioned before, eleven of these patients had liver
56
57
58
59
60

Castéra *et al.*

1
2
3 stiffness values >7.2 kPa at first examination, suggestive of the presence of significant fibrosis.
4
5 Their characteristics are detailed in Table 3. These patients did not differ from the other 190 IC
6
7 for most baseline characteristics (age, gender, BMI, ALT, AST, and platelet count), FT and APRI,
8
9 and TE success rate, except for the IQR/median value ratio (mean 0.21 ± 0.08 vs. 0.16 ± 0.07 ,
10
11 respectively, $p<0.03$). During follow-up, liver stiffness values returned to values below 7.2 kPa in
12
13 all patients except two. These two patients (number 1 and 6) underwent liver biopsy. Patient
14
15 number 1 had moderate fibrosis (F2) whereas patient number 6 had severe fibrosis (F3). Both
16
17 were offered antiviral treatment.
18
19
20

21
22 Table 4 shows the median intra-patient changes in liver stiffness, FT, APRI, AST, ALT and
23
24 HBV DNA values at different time points relative to baseline in the 82 IC patients who
25
26 underwent at least 2 determinations of non invasive methods over time. Globally, the liver
27
28 stiffness changes observed in 82 patients at the end of follow-up (last determination available)
29
30 relative to baseline were not significant, although there was a trend toward a decrease in liver
31
32 stiffness over time (median intra-patient changes at end of follow-up: -0.2 ($-1.2 - +0.7$) kPa,
33
34 $p=0.12$). As shown in Figure 3A, there were differences among individual patients, however, the
35
36 median intra-patient liver stiffness changes relative to baseline were not significant: $+0.1$ ($-0.9 -$
37
38 $+0.5$) kPa ($p=0.41$) at 2nd determination and -0.1 ($-0.9 - +0.5$) kPa ($p=0.33$) at 3rd determination
39
40 (Table 4). Similarly, no significant change was observed for AST, ALT and HBV DNA levels at
41
42 the end of follow-up relative to baseline (Table 3).
43
44
45
46

47
48 Conversely, a significant increase in FT values was observed over time: median of intra-
49
50 patient changes in FT values at the end of follow-up relative to baseline ($+0.03$ ($-0.04 - +0.09$),
51
52 $p=0.012$) (Table 4). Patients had significantly higher values at the end of follow-up than at
53
54 baseline (median 0.19 ($0.12 - 0.32$) vs. (0.16 ($0.10 - 0.24$) $p=0.012$)). Five patients (6%) had at
55
56 baseline FT values suggestive of significant fibrosis (>0.48) but none of cirrhosis (>0.74)). During
57
58
59
60

1
2
3 follow-up, FT values remained comprised between 0.48 and 0.74 in these 5 patients. As shown in
4
5 Figure 3B, there were important differences among individual patients and FT values fluctuated
6
7 over time: as a result, median intra-patient FT changes relative to baseline were significant: +0.03
8
9 (-0.03 - +0.07) (p=0.03) at 2nd determination and +0.05 (-0.03 - +0.11) (p=0.001) at 3rd
10
11 determination (Table 4).
12
13

14
15 As for APRI, there were also differences among individual patients and APRI values
16
17 fluctuated over time (Figure 3C). A significant decrease was observed over time: median of intra-
18
19 patient changes at the end of follow-up relative to baseline (-0.01 (-0.07 - +0.03), p<0.05) (Table
20
21 4).
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

The results of the present study, based on a large series of consecutive HBeAg-negative HBV patients, suggest that non invasive tools for liver fibrosis assessment, particularly TE, may be useful for liver fibrosis assessment and follow-up of IC.

Among the different available non invasive methods, we chose to evaluate two different and complementary approaches: i) a physical approach based on the measurement of liver stiffness using TE; ii) a biological approach based on serum biomarkers including a patented algorithm (FT) and a free non patented index (APRI) (31). These three non invasive methods are by far the most widely used and validated (32-34).

In the cross-sectional part of the study, we first validated the performances of TE, FT and APRI against liver biopsy for diagnosing significant fibrosis and cirrhosis in our population. TE had better diagnostic accuracy for cirrhosis (AUROC 0.89) than for significant fibrosis (0.76), as previously reported in hepatitis C (32) and hepatitis B (21, 35, 36). Interestingly, the TE cut-off we found for significant fibrosis (7.1 kPa) is similar to the one we proposed initially in chronic hepatitis C (16) and close to those recently proposed in chronic hepatitis B by Marcellin *et al.* (7.2 kPa) (21), as well as other groups (35, 36). As for cirrhosis, our cut-off (9.6 kPa) is lower than in hepatitis C (12.5 kPa) (16) but close to those proposed in hepatitis B (21, 23, 35, 36). The higher prevalence of macronodular cirrhosis in chronic hepatitis B than in hepatitis C as well as differences in the prevalence of cirrhosis in the different studied populations may account for these differences. As for FT and APRI, their performances were in keeping with those previously reported in hepatitis B (24, 37-39). Interestingly, although performance did not differ between the three methods for the diagnostic of significant fibrosis, TE had better diagnostic accuracy than FT for cirrhosis, a finding consistent with our experience in patients with chronic hepatitis C (40). In

1
2
3 that respect, some authors have proposed algorithms combining TE with serum biomarkers to
4
5 increase diagnostic accuracy for advanced fibrosis in patients with chronic hepatitis B (41).
6
7

8 Although liver biopsy remains important for determining active disease (42), it is not feasible
9
10 or necessary to biopsy all HBeAg-negative patients with near normal ALT and relatively low
11
12 HBV DNA levels (43). Non invasive tests could provide an additional adjunct for separating
13
14 patients with inactive and minimal fibrosis from those for whom a liver biopsy could be
15
16 mandated. Liver stiffness values in our series of 201 IC were low and similar to those reported in
17
18 two recent series of healthy individuals with (44) and without (45) liver biopsy as well as in
19
20 patients with chronic hepatitis C and persistently normal ALT (46). In addition, liver stiffness
21
22 values were significantly lower than in CHB patients and consistent with those previously
23
24 reported in IC (36, 47). However, no serum fibrosis biomarker was evaluated in these two studies
25
26 (36, 47). Interestingly, both APRI and FT values were low in our IC as previously reported (38)
27
28 and significantly lower than in CHB patients.
29
30
31
32

33
34 As a new definition of IC has been recently proposed (4), we also examined the results of non
35
36 invasive tests according to HBV DNA levels. Approximately 80% of our IC patients had HBV
37
38 DNA levels <2 000 IU/ml, corresponding to this new definition, a finding in keeping with those
39
40 of a recent series of 85 IC where 23% of patients had HBV DNA <2 000 IU/mL (48).
41
42 Interestingly, TE, FT and APRI values did not differ according to HBV DNA levels in IC
43
44 whereas they were significantly higher in patients with HBV DNA >20 000 IU/mL. Such findings
45
46 are consistent with those of Papatheodoridis *et al.* (43) showing that in patients with persistently
47
48 normal ALT and HBV DNA <20 000 IU/L, the 2000 IU/L cut-off does not allow discriminating
49
50 between patients with and without significant fibrosis on liver biopsy.
51
52
53
54

55 In the second longitudinal part of the study, we thoroughly evaluated the evolution of TE, FT
56
57 and APRI over time by measuring median intra-patients changes at different time points relative
58
59
60

Castéra *et al.*

1
2
3 to baseline in 82 IC with repeated examinations (2 to 4 examinations). Interestingly, although
4 some differences were observed among individual patients (Figure 3), liver stiffness values were
5 stable over time, as were AST, ALT and HBV DNA levels. Conversely, significant fluctuations
6 were observed with FT and APRI.
7
8
9

10
11
12 We have no clear explanation for this latter finding. In the only study were FT was assessed
13 longitudinally in 160 IC (38), reproducibility was deemed excellent but no data were provided
14 regarding the median or mean FT values over time. It is possible that some components of FT
15 such as bilirubin levels or apha2-macroglobulin may fluctuate over time (49). Similarly with
16 APRI, AST and platelet may fluctuate over time. Concerning TE, it has been shown to be highly
17 reproducible (50) and fluctuations of liver stiffness over time are mainly related to acute
18 inflammation or ALT flares (22, 36, 51), which are usually not observed in IC.
19
20
21
22
23
24
25
26
27
28

29 Interestingly, eleven out of 201 IC (5.5%) had baseline elevated liver stiffness values (> 7.2
30 kPa), suggestive of the presence of significant fibrosis. During follow-up, liver stiffness values
31 returned to values below 7.2 kPa in all patients but two. It should be noted that when compared to
32 the other IC, these 11 patients had significantly higher TE IQR/median value ratio. The
33 importance of this ratio for accuracy of TE results has been recently emphasized (52). This
34 finding suggests that when liver stiffness values are elevated (>7.2 kPa) in patients with a profile
35 of IC, TE should be repeated before taking a liver biopsy, to make sure that IQR/median value
36 ratio is satisfactory. Indeed, in the two patients with baseline elevated liver stiffness values
37 confirmed on a second examination, liver biopsy revealed the presence of significant fibrosis in
38 both cases (F2 and F3), suggesting that TE in this context is a sensitive tool for detection of
39 significant fibrosis.
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54
55 In conclusion, our results suggest that non invasive tools for liver fibrosis assessment,
56 particularly transient elastography, could be useful, in addition to HBV DNA and transaminase
57
58
59
60

1
2
3 levels, for follow-up of HBV inactive carriers as well as better selection of patients who require a
4
5 liver biopsy.
6
7
8
9

10 **Acknowledgments:**

11
12 We are grateful to Dr Françoise Roudot-Thoraval for her helpful statistical comments on the
13
14 manuscript.
15
16
17

18
19 **Conflicts of interest:** nothing to disclose
20
21
22

23
24 **Financial support:** none
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Dienstag JL. Hepatitis B virus infection. *N Engl J Med* 2008;**359**:1486-500.
2. Zarski JP, Marcellin P, Leroy V, *et al.* Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. *J Hepatol* 2006;**45**:355-60.
3. Brunetto MR, Oliveri F, Coco B, *et al.* Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. *J Hepatol* 2002;**36**:263-70.
4. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. *J Hepatol* 2009;**50**:227-42.
5. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. *Hepatology* 2009;**50**:661-2.
6. Castera L, Negre I, Samii K, *et al.* Pain experienced during percutaneous liver biopsy. *Hepatology* 1999;**30**:1529-30.
7. Castera L, Negre I, Samii K, *et al.* Patient-administered nitrous oxide/oxygen inhalation provides safe and effective analgesia for percutaneous liver biopsy: a randomized placebo-controlled trial. *Am J Gastroenterol* 2001;**96**:1553-7.
8. Cadranet JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). *Hepatology* 2000;**32**:477-81.
9. Piccinino F, Sagnelli E, Pasquale G, *et al.* Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. *J Hepatol* 1986;**2**:165-73.
10. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. *Hepatology* 2003;**38**:1449-57.
11. Regev A, Berho M, Jeffers LJ, *et al.* Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. *Am J Gastroenterol* 2002;**97**:2614-8.

12. Castera L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. *J Viral Hepat* 2009;**16**:300-314.
13. Pinzani M, Vizzutti F, Arena U, *et al.* Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. *Nat Clin Pract Gastroenterol Hepatol* 2008;**5**:95-106.
14. Castera L, Pinzani M. Non-invasive assessment of liver fibrosis: are we ready? *Lancet* 2010;**375**:1419-20.
15. Sandrin L, Fourquet B, Hasquenoph JM, *et al.* Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. *Ultrasound Med Biol* 2003;**29**:1705-13.
16. Castera L, Vergniol J, Foucher J, *et al.* Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. *Gastroenterology* 2005;**128**:343-50.
17. Ziol M, Handra-Luca A, Kettaneh A, *et al.* Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. *Hepatology* 2005;**41**:48-54.
18. Wai CT, Greenson JK, Fontana RJ, *et al.* A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology* 2003;**38**:518-26.
19. Imbert-Bismut F, Ratziu V, Pieroni L, *et al.* Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. *Lancet* 2001;**357**:1069-75.
20. Castera L, Denis J, Babany G, *et al.* Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: Time for new guidelines? *J Hepatol* 2007;**46**:528-529.
21. Marcellin P, Ziol M, Bedossa P, *et al.* Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. *Liver Int* 2009;**29**:242-7.

Castéra *et al.*

- 1
2
3 22. Coco B, Oliveri F, Maina AM, *et al.* Transient elastography: a new surrogate marker of liver
4 fibrosis influenced by major changes of transaminases. *J Viral Hepat* 2007;**14**:360-9.
5
6
- 7 23. Chan HL, Wong GL, Choi PC, *et al.* Alanine aminotransferase-based algorithms of liver
8 stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic
9 hepatitis B. *J Viral Hepat* 2009;**16**:36-44.
10
11
- 12 24. Sebastiani G, Vario A, Guido M, *et al.* Sequential algorithms combining non-invasive
13 markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. *World J*
14 *Gastroenterol* 2007;**13**:525-31.
15
16
- 17 25. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000--summary of a
18 workshop. *Gastroenterology* 2001;**120**:1828-53.
19
20
- 21 26. Intraobserver and interobserver variations in liver biopsy interpretation in patients with
22 chronic hepatitis C. The French METAVIR Cooperative Study Group. *Hepatology*
23 1994;**20**:15-20.
24
25
- 26 27. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The
27 METAVIR cooperative study group. *Hepatology* 1996;**24**:289-93.
28
29
- 30 28. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient
31 elastography. *J Hepatol* 2008;**48**:835-47.
32
33
- 34 29. Castera L, Foucher J, Bernard PH, *et al.* Pitfalls of liver stiffness measurement: A 5-year
35 prospective study of 13,369 examinations. *Hepatology* 2010;**51**:828-835.
36
37
- 38 30. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating
39 characteristic curves derived from the same cases. *Radiology* 1983;**148**:839-43.
40
41
- 42 31. Castera L, Pinzani M. Biopsy and non-invasive methods for the diagnosis of liver fibrosis:
43 does it take two to tango? *Gut* 2010;**59**:861-6.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 32. Friedrich-Rust M, Ong MF, Martens S, *et al.* Performance of transient elastography for the
4 staging of liver fibrosis: a meta-analysis. *Gastroenterology* 2008;**134**:960-74.
5
6
7
8 33. Poynard T, Morra R, Halfon P, *et al.* Meta-analyses of Fibrotest diagnostic value in chronic
9 liver disease. *BMC Gastroenterol* 2007;**7**:40.
10
11
12 34. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet
13 ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. *Hepatology*
14 2007;**46**:912-21.
15
16
17 35. Wang JH, Changchien CS, Hung CH, *et al.* FibroScan and ultrasonography in the prediction
18 of hepatic fibrosis in patients with chronic viral hepatitis. *J Gastroenterol* 2009;**44**:439-46.
19
20
21
22 36. Oliveri F, Coco B, Ciccorossi P, *et al.* Liver stiffness in the hepatitis B virus carrier: a non-
23 invasive marker of liver disease influenced by the pattern of transaminases. *World J*
24 *Gastroenterol* 2008;**14**:6154-62.
25
26
27 37. Myers RP, Tainturier MH, Ratziu V, *et al.* Prediction of liver histological lesions with
28 biochemical markers in patients with chronic hepatitis B. *J Hepatol* 2003;**39**:222-30.
29
30
31 38. Ngo Y, Benhamou Y, Thibault V, *et al.* An accurate definition of the status of inactive
32 hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load.
33 *PLoS One* 2008;**3**:e2573.
34
35
36 39. Chang PE, Lui HF, Chau YP, *et al.* Prospective evaluation of transient elastography for the
37 diagnosis of hepatic fibrosis in Asians: comparison with liver biopsy and aspartate
38 transaminase platelet ratio index. *Aliment Pharmacol Ther* 2008;**28**:51-61.
39
40
41
42
43
44
45
46
47
48
49
50 40. Castera L, Le Bail B, Roudot-Thoraval F, *et al.* Early detection in routine clinical practice of
51 cirrhosis and oesophageal varices in chronic hepatitis C: Comparison of transient
52 elastography (FibroScan) with standard laboratory tests and non-invasive scores. *J Hepatol*
53 2009;**50**:59-68.
54
55
56
57
58
59
60

Castéra *et al.*

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
41. Wong GL, Wong VW, Choi PC, *et al.* Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. *Aliment Pharmacol Ther* 2010;**31**:1095-103.
 42. Kumar M, Sarin SK, Hissar S, *et al.* Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. *Gastroenterology* 2008;**134**:1376-84.
 43. Papatheodoridis GV, Manesis EK, Manolakopoulos S, *et al.* Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection? *Hepatology* 2008;**48**:1451-9.
 44. Fung J, Lai CL, Chan SC, *et al.* Correlation of liver stiffness and histological features in healthy persons and in patients with occult hepatitis B, chronic active hepatitis B, or hepatitis B cirrhosis. *Am J Gastroenterol* 2010;**105**:1116-22.
 45. Roulot D, Czernichow S, Le Clesiau H, *et al.* Liver stiffness values in apparently healthy subjects: Influence of gender and metabolic syndrome. *J Hepatol* 2008;**48**:606-613.
 46. Castera L, Foucher J, Bertet J, *et al.* FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases. *Hepatology* 2006;**43**:373-4.
 47. Maimone S, Calvaruso V, Pleguezuelo M, *et al.* An evaluation of transient elastography in the discrimination of HBeAg-negative disease from inactive hepatitis B carriers. *J Viral Hepat* 2009;**16**:769-74.
 48. Papatheodoridis GV, Chrysanthos N, Hadziyannis E, *et al.* Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection. *J Viral Hepat* 2008;**15**:434-41.

- 1
2
3 49. Poynard T, Munteanu M, Imbert-Bismut F, *et al.* Prospective Analysis of Discordant Results
4
5 between Biochemical Markers and Biopsy in Patients with Chronic Hepatitis C. Clin Chem
6
7 2004;**10**:10.
8
9
10 50. Fraquelli M, Rigamonti C, Casazza G, *et al.* Reproducibility of transient elastography in the
11
12 evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007;**56**:968-73.
13
14 51. Arena U, Vizzutti F, Corti G, *et al.* Acute viral hepatitis increases liver stiffness values
15
16 measured by transient elastography. Hepatology 2008;**47**:380-4.
17
18
19 52. Lucidarme D, Foucher J, Le Bail B, *et al.* Factors of accuracy of transient elastography
20
21 (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatology 2009:1083-
22
23 89.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Castéra *et al.*

Table 1. Characteristics of the 329 HBeAg-negative patients at the time of fibrosis evaluation according to their status: inactive carriers and chronic active hepatitis (CHB) patients.

	HBeAg-negative Total (n=329)	Inactive carriers (n=201)	HBeAg-negative CHB patients (n=128)	p
Gender (Male)	62%	54%	76%	<0.0001
Age (yrs)	39 ± 14	36 ± 12	44 ± 16	<0.0001
BMI (kg/m ²)	24.0 ± 3.9	23.7 ± 3.8	24.4 ± 4.1	NS
ALT (IU/L) (N<50)	46 ± 70	27 ± 11	75 ± 106	<0.0001
AST (IU/L) (N<50)	37 ± 41	27 ± 8	55 ± 61	<0.0001
Platelets (10 ⁹ /L)	227 ± 72	237 ± 67	213 ± 79	0.004
HBV DNA (IU/mL)	2.7 ± 17.1 10 ⁶	1.5 ± 2.7 10 ³	7.4 ± 27.9 10 ⁶	0.0002

Table 2. Diagnostic performances of transient elastography (TE), Fibrotest (FT), and APRI in the 60 patients with a liver biopsy.

Method	AUROC (95% CI)	Endpoint	Cut-offs	Se (%)	Sp (%)	PPV (%)	NPV (%)	+LR	-LR	Correctly classified
TE	0.76 (0.63-0.90)	F \geq 2	> 7.1 kPa*	68	63	83	42	1.84	0.51	67%
FT	0.71 (0.58-0.85)		> 0.48	61	81	90	43	3.21	0.48	67%
APRI	0.66 (0.50-0.82)		< 0.5	62	64	38	64	1.72	0.59	
			\geq 1.5	14	100	100	30	inf	0.86	27%
TE	0.89** (0.80-0.98)	F4	> 9.6 kPa*	87	80	59	95	4.35	0.16	82%
			> 11.0 kPa	73	87	65	91	5.31	0.31	83%
FT	0.74 (0.58-0.90)		> 0.74	47	91	67	84	5.20	0.58	80%
APRI	0.79 (0.67-0.91)		< 1.0	47	80	44	82	2.35	0.66	
			\geq 2.0	13	96	50	76	3.25	0.90	63%

* optimized cut-offs in our population; **p<0.03 vs FT.

Table 3. Characteristics of the 11 inactive carriers patients with baseline elevated liver stiffness values (>7.2 kPa) with repeated measurements.

Patients	Gender /age	BMI (kg/m ²)	ALT B-line (IU/L)	HBV DNA B-line (IU/L)	LSM B-line (kPa)	FT B-line	APRI B-line	<u>Delay B-line & EOF (days)</u>	<u>LSM 2nd (kPa)</u>	<u>LSM 3rd (kPa)</u>	<u>LSM 4th (kPa)</u>	<u>FT 2nd</u>	<u>FT 3rd</u>	<u>FT 4th</u>	<u>APRI 2nd</u>	<u>APRI 3rd</u>	<u>APRI 4th</u>	ALT EOF (IU/L)	HBV DNA EOF (IU/L)	LB
1	M/25	21.6	33	7536	7.4	0.12	0.24	<u>460</u>	<u>7.3</u>	<u>6.5</u>	<u>7.8</u>	<u>0.09</u>	<u>0.16</u>	<u>0.20</u>	<u>0.17</u>	<u>0.23</u>	<u>0.23</u>	35	7325	F2
2	F/25	19.7	24	<12	7.8	0.17	0.13	<u>182</u>	<u>4.1</u>	<u>5.8</u>	-	<u>0.22</u>	<u>0.14</u>	-	<u>0.19</u>	<u>0.17</u>	-	32	<12	No
3	M/49	27.1	35	<12	7.8	0.20	0.24	<u>179</u>	<u>6.8</u>	-	-	<u>0.18</u>	-	-	<u>0.26</u>	-	-	35	<12	No
4	M/31	20.5	18	315	7.9	0.13	0.25	<u>253</u>	<u>5.9</u>	-	-	<u>0.22</u>	-	-	<u>0.32</u>	-	-	23	<12	No
5	M/52	23.4	47	1600	8.0	0.43	0.08	<u>236</u>	<u>5.4</u>	<u>4.8</u>	-	<u>0.33</u>	<u>0.28</u>	-	<u>0.10</u>	<u>0.09</u>	-	34	973	No
6	M/18	21.8	24	662	8.2	0.11	0.41	<u>395</u>	<u>9.8</u>	<u>9.5</u>	<u>12.7</u>	<u>0.12</u>	<u>0.08</u>	<u>0.06</u>	<u>0.28</u>	<u>0.35</u>	<u>0.36</u>	21	372	F3
7	M/59	24.9	29	<12	8.6	0.34	0.60	<u>247</u>	<u>6.3</u>	-	-	<u>0.30</u>	-	-	<u>0.51</u>	-	-	20	<12	No
8	M/22	24.6	25	1782	8.8	0.16	0.54	<u>100</u>	<u>5.9</u>	-	-	<u>0.15</u>	-	-	<u>0.54</u>	-	-	29	1239	No
9	M/45	23.4	38	774	9.4	0.14	0.31	<u>186</u>	<u>6.1</u>	<u>6.7</u>	<u>6.6</u>	<u>0.10</u>	<u>0.27</u>	<u>0.20</u>	<u>0.35</u>	<u>0.44</u>	<u>0.38</u>	38	118	No
10	M/23	19.6	21	9380	9.5	0.06	0.21	<u>416</u>	<u>6.9</u>	<u>6.8</u>	-	<u>0.13</u>	<u>0.12</u>	-	<u>0.17</u>	<u>0.20</u>	-	9	9216	No
11	M/26	26.4	40	566	11.6	0.41	0.36	<u>329</u>	<u>5.8</u>	<u>5.3</u>	<u>4.9</u>	<u>0.30</u>	<u>0.42</u>	<u>0.58</u>	<u>0.43</u>	<u>0.35</u>	<u>0.46</u>	42	715	No

BMI body mass index; M male gender; F female gender; LSM liver stiffness measurement; FT Fibrotest; LB liver biopsy; B-line baseline; EOF: end of follow-up.

Table 4. Median (IQR) intra-patient liver stiffness, Fibrotest®, APRI, AST, ALT and HBV DNA values changes at different time points relative to baseline in inactive carriers patients with at least 2 determinations of non invasive methods over time (End of follow-up (EOF): last determination available).

Patients	Time point	Liver stiffness (kPa)	p	Fibrotest®	p	APRI	p	AST (IU/L)	p	ALT (IU/L)	p	HBV DNA (IU/L)	p
2 time points (n=82)	EOF	-0.2 (-1.2 - +0.7)	0.12	+0.03 (-0.04 - +0.09)	0.012	-0.01 (-0.07 - +0.03)	<0.05	<u>0.0</u> (-4.0 - +4.0)	<u>0.99</u>	<u>0.0</u> (-6.0 - +5.0)	<u>0.64</u>	<u>0.0</u> (-461 - +290)	<u>0.98</u>
3 time points (n=48)	2 nd	+0.1 (-0.9 - +0.5)	0.41	+0.03 (-0.03 - +0.07)	0.03	-0.02 (-0.06 - +0.02)	0.02	<u>0.0</u> (-5.5 - +3.0)	<u>0.28</u>	<u>-2.0</u> (-9.0 - +2.0)	<u>0.10</u>	<u>117.0</u> (-509 - +3230)	<u>0.14</u>
	3 rd	-0.1 (-0.9 - +0.5)	0.33	+0.05 (-0.03 - +0.11)	0.001	-0.01 (-0.08 - +0.04)	0.41	<u>0.5</u> (-3.8 - +5.0)	<u>0.99</u>	<u>0.0</u> (-5.0 - +4.0)	<u>0.80</u>	<u>0.0</u> (-770 - +848)	<u>0.82</u>
4 time points (n=27)	2 nd	+0.2 (-0.8 - +0.9)	0.98	0.00 (-0.04 - +0.06)	0.55	0.00 (-0.06 - +0.04)	0.45	<u>2.0</u> (-4.0 - +4.0)	<u>0.60</u>	<u>0.0</u> (-3.0 - +7.0)	<u>0.90</u>	<u>117.0</u> (-422 - +4076)	<u>0.18</u>
	3 rd	-0.1 (-1.0 - +0.5)	0.50	+0.07 (0.00 - +0.13)	0.002	+0.02 (-0.06 - +0.06)	0.71	<u>2.0</u> (-2.0 - +6.0)	<u>0.22</u>	<u>2.0</u> (-3.0 - +7.0)	<u>0.09</u>	<u>-70.0</u> (-1786 - +91)	<u>0.21</u>
	4 th	+0.1 (-1.1 - +0.9)	0.88	+0.05 (-0.02 - +0.09)	0.08	+0.01 (-0.05 - +0.05)	0.75	<u>3.0</u> (-1.0 - +5.0)	<u>0.07</u>	<u>3.0</u> (-1.3 - +9.0)	<u>0.03</u>	<u>4.0</u> (-1806 - +244)	<u>0.89</u>

EOF: end of follow-up; p values are for intra-patients changes relative to baseline.


Legend for figures

Figure 1. Box plots of liver stiffness (A), Fibrotest® (B), and APRI (C) values in the 201 IC patients and the 128 CHB patients. The top and bottom of the boxes are the first and third quartiles, respectively. The length of the box thus represents the IQR within which 50% of the values were located. The line through the middle of each box represents the median. The error bars show the minimum and maximum values (range).

Figure 2. Box plots of liver stiffness (A), Fibrotest® (B), and APRI (C) values in the 201 IC patients according to HBV DNA levels. The top and bottom of the boxes are the first and third quartiles, respectively. The length of the box thus represents the IQR within which 50% of the values were located. The line through the middle of each box represents the median. The error bars show the minimum and maximum values (range).

Figure 3. Evolution over time of liver stiffness (A), Fibrotest® (B), and APRI (C) values in the 48 inactive carriers patients who underwent three determinations over time (median: 23.1 months; range: 10.1-34.7). Median intra-patient changes at different time points relative to baseline (top) and individual data (bottom).

Figure 1



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Figure 2

Figure 3

